98%
921
2 minutes
20
The incidence of diabetic retinopathy (DR) has been found to be associated with the risk of developing Alzheimer's disease (AD). In addition to the common properties of neurodegeneration, their progressions are involved with abnormal vascular functions. However, the interactions between them have not been fully understood. This study aimed to investigate the key factor for the underlying interactions and shared signaling pathways in the vasculature of DR and AD. We retrieved single-cell RNA sequencing (scRNA-seq) data regarding human fibrovascular membrane (FVM) of proliferative diabetic retinopathy (PDR) and human hippocampus vessels of AD from the NCBI-GEO database. GSEA analysis was performed to analyze AD-related genes in endothelial cells and pericytes of PDR. CellChat was used for predicting cell-cell communication and the signaling pathway. The data suggested that amyloid-beta precursor protein (APP) signaling was found crucial in the vasculature of PDR and AD. Endothelial cells and pericytes could pose influences on other cells mainly via APP signaling in PDR. The endothelial cells were mainly coordinated with macrophages in the hippocampus vasculature of AD via APP signaling. The bulk RNA-seq in mice with PDR validated that the expression of APP gene had a significant correlation with that of the AD genome-wide association studies (GWAS) gene. Our study demonstrates that the vasculopathy of PDR and AD is likely to share a common signaling pathway, of which the APP-related pathway is a potential target.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10847282 | PMC |
http://dx.doi.org/10.3389/fcell.2023.1328979 | DOI Listing |
Jpn J Ophthalmol
September 2025
Department of Ophthalmology, Osaka University Graduate School of Medicine, Room E7, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Abtract: PURPOSE: To evaluate the correlation between corneal backscatter and visual function in patients with Fuchs endothelial corneal dystrophy (FECD).
Study Design: Prospective case series.
Methods: This study included 53 eyes from 38 patients with FECD.
Graefes Arch Clin Exp Ophthalmol
September 2025
Department of Physics of Condensed Matter, Optics Area. Vision Research Group (CIVIUS), University of Seville, Avenida de la Reina Mercedes s/n (41012), Seville, Spain.
Purpose: To analyze the relationship between various visual function parameters (refractive status, visual acuity and contrast sensitivity) and macular pigment optical density (MPOD) values, as well as dietary intake of lutein and zeaxanthin in a pediatric population.
Methods: Thirty-six healthy White pediatric patients participated in this cross-sectional study conducted at the Optometry Clinic (Faculty of Pharmacy, Seville, Spain). MPOD values were measured using the MPSII (Macular Pigment Screener II).
Br J Clin Pharmacol
September 2025
Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria.
Aims: Late-diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost-benefit of screening programmes for DR.
View Article and Find Full Text PDFFood Res Int
November 2025
Department of Chemical Engineering, Chung Yuan Christian University, Taoyuan City 320, Taiwan. Electronic address:
Microalgae and their rich nutrient content are increasingly recognized as a sustainable food source. Microalgal macular pigment (MP), composed of zeaxanthin and lutein, is densely concentrated in the retinal macula of eyes and is frequently utilized in eye health maintenance. However, as a sustainable food ingredient, the food safety and functionality of MP need further investigated.
View Article and Find Full Text PDFCan J Ophthalmol
September 2025
Department of Pharmacy, The First Affiliated Hospital of Air Force Military Medical University, Xi'an, Shaanxi, People's Republic of China.. Electronic address:
Objective: This study aims to evaluate the relationship between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and diabetic retinopathy (DR) in diabetes mellitus.
Methods: We conducted a systematic search in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov from their inception to November 9, 2024, for randomized controlled trials (RCTs) and real-world studies of SGLT2i in the treatment of diabetes mellitus.